Skip to main content

Table 1 Patients’ characteristics at the baseline before and after matching

From: Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis

  Before matching After matching
nCRT (%) nCT (%) P nCRT (%) nCT (%) P
All patients 81 89   60 60  
Age    0.273    0.707
 ≥ 60 49 (60.5) 61 (68.5)   38 (63.3) 36 (60.0)  
 < 60 32 (39.5) 28 (31.5)   22 (36.7) 24 (40.0)  
Sex    0.062    0.509
 Male 75 (92.6) 74 (83.1)   56 (93.3) 54 (90.0)  
 Female 6 (7.4) 15 (16.9)   4 (6.7) 6 (10.0)  
Siewert type    0.000    0.456
 II 42 (51.9) 22 (24.7)   26 (43.3) 22 (36.7)  
 III 39 (48.1) 67 (75.3)   34 (56.7) 38 (63.3)  
ECOG    0.193    0.729
 0 9 (11.1) 5 (5.6)   4 (6.7) 5 (8.3)  
 1 72 (88.9) 84 (94.4)   56 (93.3) 55 (91.7)  
cT    0.030    0.822
 3 24 (29.6) 14 (15.7)   13 (21.7) 12 (20.0)  
 4 57 (70.4) 75 (84.3)   47 (78.3) 48 (80.0)  
cN    0.902    0.500
 N0 17 (21.0) 18 (20.2)   14 (23.3) 11 (18.3)  
 N+ 64 (79.0) 71 (79.8)   46 (76.7) 49 (81.7)  
Her-2    0.258    0.395
 Unknown 35 (43.2) 47 (52.8)   26 (43.3) 25 (41.7)  
 0/1 28 (34.6) 29 (32.6)   21 (35.0) 24 (40.0)  
 2+ 15 (18.5) 8 (9.0)   11 (18.3) 6 (10.0)  
 3+ 3 (3.7) 5 (5.6)   2 (3.3) 5 (8.3)  
  1. cT clinical T stage, cN clinical N stage